EU yes for Vertex's Kalydeco in cystic fibrosis
This article was originally published in Scrip
The European Commission has approved Vertex Pharmaceuticals’ cystic fibrosis drug Kalydeco (ivacaftor), which received CHMP recommendation just two months ago (scripintelligence.com, 25 May 2012).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.